Skip to main content
Clinical Trials/NL-OMON48956
NL-OMON48956
Completed
Not Applicable

Clinical trial to evaluate safety and dose response using the C2 CryoBalloonTM 180 Ablation system for the treatment of dysplastic Barrett*s esophagus - C2 CryoBalloon 180 Ablation System Dose Response Study

C2 Therapeutics, contactpersoon Marcia Wachna0 sites25 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
C2 Therapeutics, contactpersoon Marcia Wachna
Enrollment
25
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
C2 Therapeutics, contactpersoon Marcia Wachna

Eligibility Criteria

Inclusion Criteria

  • Patients must meet ALL of the following criteria to be eligible for
  • participation in the study:
  • 1\. Flat\- type BE esophagus, with an indication for ablation therapy, defined as:
  • a. Diagnosis of LGD or HGD in BE (confirmed by baseline histopathological
  • analysis), OR
  • b. Residual BE with any grade of dysplasia after endoscopic resection (EMR or
  • ESD) to treat non\-flat BE, \*6 weeks prior to enrolling the patient to this
  • study. The ER pathology should indicate endoscopic treatment (i.e. only mucosal
  • invasion or limited submucosal invasion (SM1\), no lymphovascular infiltration,
  • free vertical resection margins and not poorly differentiated)

Exclusion Criteria

  • 1\. Esophageal stenosis preventing advancement of a therapeutic endoscope.
  • 2\. Any endoscopically visualized lesion such as ulcers, masses or nodules.
  • Neoplastic nodules must first be treated with ER \>6 weeks prior to planned
  • treatment under this protocol.
  • 3\. Prior ER of more than 2cm in length or \>50% of the esophageal lumen
  • circumference
  • 4\. History of locally advanced (\>SM1\) esophageal cancer
  • 5\. History of esophageal varices
  • 6\. Prior distal esophagectomy
  • 7\. Active esophagitis LA grade B or higher

Outcomes

Primary Outcomes

Not specified

Similar Trials